Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials

Journal article

Open access

Peer reviewed

Elisabet E Manasanch, Neha Korde, Sham Mailankody, Nishant Tageja, Manisha Bhutani, Mark Roschewski, Ola Landgren and Carl Ola Landgren

Haematologica (Roma), Vol.99(12), pp.1769-1771

2014-12

PMCID: PMC4258744

PMID: 25472951

Abstract

Antineoplastic Agents - therapeutic use

Clinical Trials as Topic

Disease Management

Humans

Monitoring, Physiologic

Multiple Myeloma - drug therapy

Prognosis

Risk Factors

url

https://doi.org/10.3324/haematol.2014.107516View

Published (Version of record) Open

2 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.130 Lymphomas; 1.130.617 Multiple Myeloma
Web Of Science research areas: Hematology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials
Creators: Elisabet E Manasanch - The University of Texas MD Anderson Cancer Center
Neha Korde - Memorial Sloan Kettering Cancer Center
Sham Mailankody - National Institutes of Health
Nishant Tageja - National Institutes of Health
Manisha Bhutani - National Institutes of Health
Mark Roschewski - National Institutes of Health
Ola Landgren - Memorial Sloan Kettering Cancer Center
Carl Ola Landgren - Miller School of Medicine
Publication Details: Haematologica (Roma), Vol.99(12), pp.1769-1771
Academic Unit: UMMG Department of Medicine; Miller School of Medicine
Language: English
Resource Type: Journal article
PMID: 25472951
PMCID: PMC4258744
Record Identifier: 991031714215102976